eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2020
vol. 45
 
Share:
Share:
abstract:
Case report

Acute tubulointerstitial nephritis following aciclovir treatment for chickenpox in children with nephrotic syndrome – a report of two cases

Małgorzata Pańczyk-Tomaszewska
1
,
Elżbieta Kuźma-Mroczkowska
1
,
Piotr Skrzypczyk
1
,
Hanna Szymanik-Grzelak
1
,
Jadwiga Małdyk
2

  1. Department of Pediatrics and Nephrology, Medical University of Warsaw, Warsaw, Poland
  2. Department of Pathology, Medical University of Warsaw, Warsaw, Poland
Centr Eur J Immunol 2020; 45 (4): 494-497
Online publish date: 2021/01/30
View full text Get citation
 
PlumX metrics:
Tubulointerstitial nephritis (TIN) is an inflammatory process primarily involving the renal interstitium and is the cause of acute kidney injury (AKI) in 3-7% of cases confirmed by renal biopsy in children. Aciclovir may have a nephrotoxic effect by crystallization in renal tubules or by inducing an immunologic process that leads to development of TIN.

We report 2 male patients, aged 10 and 8 years, with nephrotic syndrome (NS), in whom disease relapse was triggered by varicella zoster infection. The patients received intravenous aciclovir which resulted in AKI due to acute TIN with the glomerular filtration rate 19.5 and 24.9 ml/min/1.73 m2, respectively. The diagnosis was confirmed by kidney biopsy in one of these patients. Initiation of glucocorticosteroids and withdrawal of aciclovir resulted in resolution of proteinuria and symptoms of AKI.

In children with active NS treated with intravenous aciclovir, a possibility of AKI due to TIN should be taken into account.
keywords:

children, nephrotic syndrome (NS), acute tubulointerstitial nephritis (TIN), acyclovir

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.